The potential use of tetracyclines in neurodegenerative diseases and the role of nano-based drug delivery systems

Rahmani, Mahdieh; Álvarez, Sofía Elisa Negro; Barcia, Emilia

doi:10.1016/j.ejps.2022.106237

Cited by 23 publications

(21 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When preparing multiparticulate drug delivery systems, a wide range of variables must be considered, each of which can have a decisive effect on the final properties of the device and consequently, on the effect obtained in vivo. Solubility characteristics of the therapeutic agent, the polymer or combination of polymers selected, the percentage of each polymer and active ingredient, solvents and cosolvent, the method of preparation, etc., are factors that can lead to different properties and behavior of the final delivery system [186]. Micro-and nano-systems exhibit different features, not only in terms of size, but also regarding their physicochemical properties, with the success of a device in the form of polymeric microparticles not necessarily reached with the same therapeutic agent and polymer when encapsulating as nanoparticles, and vice versa [78].…”

Section: Discussionmentioning

confidence: 99%

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

et al. 2022

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a devastating neurodegenerative disease characterized by progressive destruction of dopaminergic tissue in the central nervous system (CNS). To date, there is no cure for the disease, with current pharmacological treatments aimed at controlling the symptoms. Therefore, there is an unmet need for new treatments for PD. In addition to new therapeutic options, there exists the need for improved efficiency of the existing ones, as many agents have difficulties in crossing the blood–brain barrier (BBB) to achieve therapeutic levels in the CNS or exhibit inappropriate pharmacokinetic profiles, thereby limiting their clinical benefits. To overcome these limitations, an interesting approach is the use of drug delivery systems, such as polymeric microparticles (MPs) and nanoparticles (NPs) that allow for the controlled release of the active ingredients targeting to the desired site of action, increasing the bioavailability and efficacy of treatments, as well as reducing the number of administrations and adverse effects. Here we review the polymeric micro- and nano-systems under investigation as potential new therapies for PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Section: The Antimicrobial Properties Of Cannabis and Cannabis-derive...mentioning

confidence: 99%

“…It must be recognized that a potential microbial etiology for neurodegenerative diseases has been postulated for some time, with the oral and gut microbiota particularly implicated, as reviewed extensively elsewhere [ 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 ]. This has fostered the possibility of the development of suitable bacteria-targeted therapeutic strategies, some of which show promise in animal models [ 80 , 81 , 84 , 85 , 86 ]. It remains to be clarified if it is a general dysbiosis, specific bacteria and their virulence factors, or both that may be most important in the development of Parkinson’s disease, Alzheimer’s disease and other neuropathologies.…”

Section: The Antimicrobial Properties Of Cannabis and Cannabis-derive...mentioning

confidence: 99%

The Antimicrobial Properties of Cannabis and Cannabis-Derived Compounds and Relevance to CB2-Targeted Neurodegenerative Therapeutics

et al. 2022

View full text Add to dashboard Cite

Cannabinoid receptor 2 (CB2) is of interest as a much-needed target for the treatment or prevention of several neurogenerative diseases. However, CB2 agonists, particularly phytocannabinoids, have been ascribed antimicrobial properties and are associated with the induction of microbiome compositional fluxes. When developing novel CB2 therapeutics, CB2 engagement and antimicrobial functions should both be considered. This review summarizes those cannabinoids and cannabis-informed molecules and preparations (CIMPs) that show promise as microbicidal agents, with a particular focus on the most recent developments. CIMP–microbe interactions and anti-microbial mechanisms are discussed, while the major knowledge gaps and barriers to translation are presented. Further research into CIMPs may proffer novel direct or adjunctive strategies to augment the currently available antimicrobial armory. The clinical promise of CIMPs as antimicrobials, however, remains unrealized. Nevertheless, the microbicidal effects ascribed to several CB2 receptor-agonists should be considered when designing therapeutic approaches for neurocognitive and other disorders, particularly in cases where such regimens are to be long-term. To this end, the potential development of CB2 agonists lacking antimicrobial properties is also discussed.

show abstract

“…Doxycycline (DOX) is another broad-spectrum antibiotic belonging to tetracyclines that has been considered as PD treatment [ 279 ]. In vitro, DOX has shown anti-inflammatory properties by interfering with p38 MAP kinase and NF-κB pathways, reducing the expression of the activated microglia marker IBA-1 and inhibiting the production of the pro-oxidant and pro-inflammatory factors ROS, nitric oxide, iNOS, cyclooxygenase-2 (COX-2), IL-1β and TNF-α [ 280 , 281 , 282 ].…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

“…Overall, contrasting results and scarce long-term safety data remain a concern. Innovative drug delivery systems based on nanoparticles are now being tested to improve the clinical benefit of these antibiotics [ 279 ]. At the same time, synthetic tailoring to potentiate the neuroprotective chemical functions over the antimicrobial ones is another promising approach for the risk-benefit optimization [ 301 ].…”

Section: Parkinson’s Disease and Gut Microbiota: Therapeutic Approachesmentioning

confidence: 99%

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Varesi¹,

Campagnoli²,

Fahmideh³

et al. 2022

IJMS

View full text Add to dashboard Cite

The bidirectional interaction between the gut microbiota (GM) and the Central Nervous System, the so-called gut microbiota brain axis (GMBA), deeply affects brain function and has an important impact on the development of neurodegenerative diseases. In Parkinson’s disease (PD), gastrointestinal symptoms often precede the onset of motor and non-motor manifestations, and alterations in the GM composition accompany disease pathogenesis. Several studies have been conducted to unravel the role of dysbiosis and intestinal permeability in PD onset and progression, but the therapeutic and diagnostic applications of GM modifying approaches remain to be fully elucidated. After a brief introduction on the involvement of GMBA in the disease, we present evidence for GM alterations and leaky gut in PD patients. According to these data, we then review the potential of GM-based signatures to serve as disease biomarkers and we highlight the emerging role of probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation as supportive therapeutic approaches in PD. Finally, we analyze the mutual influence between commonly prescribed PD medications and gut-microbiota, and we offer insights on the involvement also of nasal and oral microbiota in PD pathology, thus providing a comprehensive and up-to-date overview on the role of microbial features in disease diagnosis and treatment.

show abstract

The potential use of tetracyclines in neurodegenerative diseases and the role of nano-based drug delivery systems

Cited by 23 publications

References 109 publications

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

The Antimicrobial Properties of Cannabis and Cannabis-Derived Compounds and Relevance to CB2-Targeted Neurodegenerative Therapeutics

The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment

Contact Info

Product

Resources

About